Paper42455481
Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies.
Marques BS and 4 others. Mol Diagn Ther, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies. Papers, record 42455481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42455481
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Temozolomide | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| CRISPR-Cas Systems | Major topic |
| Antineoplastic Agents, Alkylating | Major topic |
| Glioblastoma | Major topic |
| Brain Neoplasms | Major topic |
| Humans | |
| Animals |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2022.06174.PTDC | Fundação para a Ciência e a Tecnologia | PubMed | ||
| UID/PRR/00313/2025 | Fundação para a Ciência e a Tecnologia | PubMed | ||
| UID/00313/2025 | Fundação para a Ciência e a Tecnologia | PubMed |
Source PubMed
References89
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41580561 | The impact of AI on modern oncology from early detection to personalized cancer treatment. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41580561 | PubMed |
| 2 | 41232838 | Integrating computational pathology and multi-transcriptomics to characterize glioblastoma heterogeneity and identify prognostic biomarkers. | Hum Pathol | 2025 | https://conductscience.org/library/papers/41232838 | PubMed |
| 3 | 38326875 | IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy. | Genome Biol | 2024 | https://conductscience.org/library/papers/38326875 | PubMed |
| 4 | 31637166 | The CRISPR-Cas13a Gene-Editing System Induces Collateral Cleavage of RNA in Glioma Cells. | Adv Sci (Weinh) | 2019 | https://conductscience.org/library/papers/31637166 | PubMed |
| 5 | 25263330 | CRISPR-Cas9 knockin mice for genome editing and cancer modeling. | Cell | 2014 | https://conductscience.org/library/papers/25263330 | PubMed |
| 6 | 39209994 | Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing. | Nat Nanotechnol | 2024 | https://conductscience.org/library/papers/39209994 | PubMed |
| 7 | 38357209 | Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells. | Front Oncol | 2024 | https://conductscience.org/library/papers/38357209 | PubMed |
| 8 | 39078737 | A simple and scalable zebrafish model of Sonic hedgehog medulloblastoma. | Cell Rep | 2024 | https://conductscience.org/library/papers/39078737 | PubMed |
| 9 | 30995489 | Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. | Cell Rep | 2019 | https://conductscience.org/library/papers/30995489 | PubMed |
| 10 | 25119044 | CRISPR-mediated direct mutation of cancer genes in the mouse liver. | Nature | 2014 | https://conductscience.org/library/papers/25119044 | PubMed |
| 11 | 40697666 | CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40697666 | PubMed |
| 12 | 38134889 | Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents. | Neuro Oncol | 2024 | https://conductscience.org/library/papers/38134889 | PubMed |
| 13 | 39799395 | Efficient gene delivery admitted by small metabolites specifically targeting astrocytes in the mouse brain. | Mol Ther | 2025 | https://conductscience.org/library/papers/39799395 | PubMed |
| 14 | 34337348 | Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. | Cancer Drug Resist | 2021 | https://conductscience.org/library/papers/34337348 | PubMed |
| 15 | 38861272 | Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma. | ACS Nano | 2024 | https://conductscience.org/library/papers/38861272 | PubMed |
| 16 | 39821288 | Myt1 Kinase: An Emerging Cell-Cycle Regulator for Cancer Therapeutics. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39821288 | PubMed |
| 17 | 40050992 | Large-scale CRISPRi screens link metabolic stress to glioblastoma chemoresistance. | J Transl Med | 2025 | https://conductscience.org/library/papers/40050992 | PubMed |
| 18 | 33005303 | CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. | Comput Struct Biotechnol J | 2020 | https://conductscience.org/library/papers/33005303 | PubMed |
| 19 | 26603103 | Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. | Nat Commun | 2015 | https://conductscience.org/library/papers/26603103 | PubMed |
| 20 | 24912512 | MGMT testing--the challenges for biomarker-based glioma treatment. | Nat Rev Neurol | 2014 | https://conductscience.org/library/papers/24912512 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42455481
GET https://conductscience.org/api/papers/v1/42455481/references?page=2